Pelthos Therapeutics CEO Engages at Healthcare Conference

Author: Dominic Sanders Updated: 12-02-2025 08:10 AM

Pelthos Therapeutics at the Annual Healthcare Conference

DURHAM, N.C. — Pelthos Therapeutics Inc. (NYSE American: PTHS), a dedicated biopharmaceutical company focused on developing innovative therapies for patients, is poised to highlight its contributions at the upcoming Piper Sandler 37th Annual Healthcare Conference. The event will take place on December 4 at The Lotte New York Palace, and Scott Plesha, the CEO of Pelthos, is set to engage in a fireside chat at 9:30 a.m. Eastern Time.

Fireside Chat Details

This is an exciting opportunity for institutional investors to gain insights directly from Mr. Plesha regarding the company's mission and goals. Investors attending the conference in person are encouraged to arrange one-on-one meetings through their Piper Sandler representatives. This interaction will provide a platform to discuss Pelthos' strategic vision and existing innovations in the biopharmaceutical landscape.

Webcast Opportunity for Remote Attendees

For those who cannot attend the conference live, Pelthos is offering a web streaming option. A live broadcast of the fireside chat will be accessible on Pelthos's News & Events page shortly after the event. This arrangement ensures that even remote investors can be a part of the conversation surrounding the latest advancements in Pelthos' therapeutic developments.

Focus on Patient-Centric Therapeutics

Pelthos Therapeutics is committed to addressing unmet patient needs through its innovative approach to biopharmaceuticals. Key among its product line is ZELSUVMI™ (berdazimer) topical gel, which is designed for the treatment of molluscum contagiosum. Approved by the U.S. Food and Drug Administration recently, ZELSUVMI represents a significant stride in offering effective solutions for conditions that have long been overlooked.

Commitment to Innovation

Pelthos' approach is not just about providing a product; it's about transforming lives through science and innovation. The company’s dedication to creating safe, efficacious treatments exemplifies its commitment to patients who often struggle with treatment options. The introduction of ZELSUVMI demonstrates Pelthos' vision of bridging the gap in therapeutic interventions.

About Pelthos Therapeutics

Pelthos Therapeutics stands out in the biopharmaceutical sector due to its unwavering focus on creating revolutionary therapies aimed at improving patient outcomes. With a roster of promising products and a commitment to clinical excellence, Pelthos is redefining treatment paradigms for various conditions. Their innovative solutions stem from rigorous research and a deep understanding of patient needs.

Contact Information

For inquiries regarding Pelthos Therapeutics, please reach out to the contacts below:

Investors:
Mike Moyer
LifeSci Advisors, LLC
Email: mmoyer@lifesciadvisors.com

Media:
Kellie Walsh
KWM Communications
Email: pelthos@kwmcommunications.com
Phone: (914) 315-6072

Frequently Asked Questions

What is Pelthos Therapeutics focused on?

Pelthos Therapeutics is dedicated to developing innovative therapeutic products aimed at addressing unmet patient needs.

When will the fireside chat take place?

The fireside chat is scheduled for December 4 at 9:30 a.m. Eastern Time during the Piper Sandler Annual Healthcare Conference.

How can investors participate?

Investors attending the conference can schedule one-on-one meetings with Pelthos’ CEO via their Piper Sandler representatives.

What product did Pelthos recently launch?

Pelthos launched ZELSUVMI™, a topical gel approved for the treatment of molluscum contagiosum.

How can I learn more about Pelthos Therapeutics?

For more information, you can visit the company's official website.

About The Author

Dominic Sanders here, a writer and financial specialist committed to helping my readers understand the world of finance. Having a strong financial background and a lot of experience, I concentrate on using my blog posts and articles to translate difficult financial subjects into understandable, doable advice. My goal in writing is to arm you with the information and skills need to make wise financial choices.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors seeking new perspectives to seasoned investors. My mission is to make money understandable and approachable so you may confidently take charge of your financial future. I appreciate you walking this road with me to success and financial literacy.

Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.